Skip to main content
Premium Trial:

Request an Annual Quote

USPTO Publishes Three RNAi-Related Patent Applications: Apr 13, 2006

Premium

Title: Oligomeric Compounds Effecting Drosha-Mediated Cleavage

Number: 20060073505

Filed: Sept. 20, 2005

Lead Inventor: Richard Griffey, Isis Pharmaceuticals

The invention, the patent application's abstract states, "provides methods of promoting Drosha-mediated cleavage of antisense oligomeric compounds and compositions and compounds for carrying out the same."


Title: Therapeutic Alteration of Transplantable Tissues Through In Situ or Ex Vivo Exposure to RNA Interference Molecules

Number: 20060073127

Filed: July 11, 2005

Lead Inventor: Timothy Kowalik, University of Massachusetts

According to the patent application's abstract, the invention, "at least in part, relates to the discovery of efficacious delivery of an RNAi agent (in preferred aspects of the invention, an siRNA) to a transplantable tissue. Organ rejection, transplantation-mediated transmission of viral infection, and triggering of apoptosis in transplanted tissues can each be minimized by the methods and compositions of the instant invention," the abstract states. "The RNAi agent(s) of the instant invention can be delivered as 'naked' molecules, or using liposomal and other modes of delivery, to transplantable tissues. Such delivery can occur via perfusion of the RNAi agent in solution through the vasculature of a whole or partial organ; or tissues including transplantable cells and cell lines may be bathed, injected or otherwise treated with RNAi agents. Preferred transplantable tissues include, for example, pancreas, liver, kidney, heart, lung, and all cells and cell lines derived from such tissues (e.g., pancreatic islet cells that may, e.g., be transplanted as a treated population)," it adds.


Title: IKKalpha- and IKKbeta-Specific Inhibitors

Number: 20060073120

Filed: Sept. 30, 2005

Lead Inventor: Jun Li, Boehringer Ingelheim

The invention, the patent application's abstract states, comprises a method for modulating NF-kappaB dependent gene transcription in a cell comprised of modulating IKKalpha and IKKbeta protein and protein activity in the cell. The … invention also provides siRNA compositions and methods thereof for modulating NF-kappaB dependent gene transcription."

The Scan

Fertility Fraud Found

Consumer genetic testing has uncovered cases of fertility fraud that are leading to lawsuits, according to USA Today.

Ties Between Vigorous Exercise, ALS in Genetically At-Risk People

Regular strenuous exercise could contribute to motor neuron disease development among those already at genetic risk, Sky News reports.

Test Warning

The Guardian writes that the US regulators have warned against using a rapid COVID-19 test that is a key part of mass testing in the UK.

Science Papers Examine Feedback Mechanism Affecting Xist, Continuous Health Monitoring for Precision Medicine

In Science this week: analysis of cis confinement of the X-inactive specific transcript, and more.